Program
mibavademab
Also written as “Mibavademab”, “REGN4461” and “Low-Dose REGN4461”.
Its studies are mostly in Obesity, Morbid · Lipodystrophy, Familial Partial · Amenorrhea · Obesity, led by 2 companies.
Drug pageMibavademab: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticalsits history only | 73 open or running | phase 3since Aug 7, 2024 | May 7, 2018 | Jun 18, 2027phase 3 · NCT07220772 |
| Eli Lilly | 10 open or running | phase 2since Apr 16, 2024 | Apr 16, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 19, 2020Named mibavademabINNProposed as its International Nonproprietary Name in WHO's List 124 · before, REGN4461
- Apr 16, 2024First study: phase 2 study in ObesityFirst studyNCT06373146 · 392 enrolled · United States
TargetBeta
“Leptin receptor agonist”ChEMBL 37, by rule
Studies
The one study Eli Lilly leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06373146Obesity · United States | 2 | Completed | Dec 15, 2025 | 392 |
How it is read
Names in the registry
- “Mibavademab”, 4 entries
- “REGN4461”, 2 entries
- “mibavademab”, 1 entry
- “Low-Dose REGN4461”, 1 entry
- “High-dose REGN4461”, 1 entry
Conditions, from the studies’ own filings
- Obesity, Morbid, 2 studies
- Lipodystrophy, Familial Partial, 2 studies
- Amenorrhea, 1 study
- Obesity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.